Santhosh Ambika (@RenoHemonc) ranks #24 among US lung cancer KOLs, #29 among US breast cancer KOLs, #15 among US gi cancer KOLs on X in 2026, by engagement from fellow physicians. 14 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: HARMONi-6, SERENA-6. CMS Open Payments lists $17,406 in 2025 general payments.
At a Glance
- 5 posts naming a trial in 2026
- 2 trials discussed by name
- Lung Cancer: US #24 · 12 physicians engaged
- Breast Cancer: US #29 · 4 physicians engaged
- GI Cancer: US #15 · 14 physicians engaged
- CMS Open Payments lists $17,406 in 2025 general payments.
This Month
What Santhosh Ambika has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #24 | — | 12 | 13 | Full ranking |
| Breast Cancer | #29 | — | 4 | 5 | Full ranking |
| GI Cancer | #15 | — | 14 | 15 |
What Colleagues Are Saying About Santhosh Ambika
2026 posts by fellow physicians that mention @RenoHemonc, quoted word for word.
Volga vs EV 303 in bladder cancer Good to see trials reducing EV exposure Both for Cisplatin ineligible If both of their HR etc look same Will people be ok not using post op EV ? Interesting time for Bladder ca @RenoHemonc - using your pic @OncBrothers @SuyogCancer https://t.co/SRxqXStcfu
Trials Santhosh Ambika Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| HARMONi-6 | 3 | #25 of 74 | May 31, 2026 |
| SERENA-6 | 2 | #26 of 39 | May 2, 2026 |
Santhosh Ambika on HARMONi-6
RT @adamfeuerstein: Here we, go #ASCO26. Ivonescimab HARMONi-6 for $SMMT Akeso and all those interested in PD1/VEGFs STAT's @matthewherpe…
RT @StephenVLiu: Dr. Shun Lu presents HARMONi-6 #ASCO26 plenary: first-line ivonescimab + chemo (carbo + pac) vs tislelizumab + chemo in sq…
RT @JacobPlieth: Akeso's Harmoni-6 wins on survival. Now on to $SMMT Harmoni-3. Via @ApexOnco from #ASCO26 -> https://t.co/9Nj3NTaAI9 $BNTX…
Santhosh Ambika on SERENA-6
@roxboxfix Ember -3 , Victoria can be squeezed in. Four light -1 ( Ph2) interesting while Serena-6 a no go .
@PTarantinoMD Grok feels like there will be OS benefit, may have to wait beyond 2028.. Grok OS prediction for SERENA-6 (camizestrant + CDK4/6i vs AI + CDK4/6i) based on the PFS data:The PFS benefit is exceptionally strong — HR 0.44 (56% risk reduction), median PFS 16.0 vs 9.2 months from
Santhosh Ambika’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
RAS(ON) LANDSCAPE #esmo2026 https://t.co/bpKd0iqgWo
Industry Payments
CMS Open Payments · 2025 general payments
$17,406 across 99 payments